NCT02713061

A Phase 2 Study of a Subcutaneous Injection of TAK-850 in Healthy Adult Participants

An Open-label Phase 2 Study to Evaluate the Safety and Immnogenicity of a Single Subcutaneous Injection of Quadrivalent TAK-850 in Healthy Adult Subjects

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Takeda · Industry
• Sex: All
• Age: 20 Years – 49 Years
• Healthy volunteers: Accepted

Summary

This clinical trial is a Phase 2 study of a single subcutaneous injection of TAK-850 for 22 days in healthy Japanese adults.

Detailed description

The primary objective of this study is to evaluate the safety and immunogenicity of a single subcutaneous injection of TAK-850 for 22 days in healthy Japanese adults.

Conditions

• Influenza Prevention

Interventions

Type	Name	Description
DRUG	TAK-850	TAK-850 injection

Timeline

• Start date: 2016-03-01
• Primary completion: 2016-04-01
• Completion: 2016-04-01
• First posted: 2016-03-18
• Last updated: 2016-08-25

Locations

1 site across 1 country: Japan